EGFR-Based Immunoisolation as a Recovery Target for Low-EpCAM CTC Subpopulation

• Ana Vila ,

  * E-mail: ana.vila@inl.int (AV); clotilde.costa.nogueira@sergas.es (CC)

  Affiliation INL–International Iberian Nanotechnology Laboratory, AvdaMestre José Veiga, 4715–330 Braga, Portugal

  ⨯
• Miguel Abal,

  Affiliation Translational Medical Oncology, Health Research Institute of Santiago (IDIS); ComplexoHospitalarioUniversitario de Santiago de Compostela (SERGAS); Trav. Choupana s/n 15706, Santiago de Compostela, Spain

  ⨯
• Laura Muinelo-Romay,

  Affiliation Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS); ComplexoHospitalarioUniversitario de Santiago de Compostela (SERGAS); Trav. Choupana s/n 15706, Santiago de Compostela, Spain

  ⨯
• Carlos Rodriguez-Abreu,

  Affiliation INL–International Iberian Nanotechnology Laboratory, AvdaMestre José Veiga, 4715–330 Braga, Portugal

  ⨯
• José Rivas,

  Affiliations INL–International Iberian Nanotechnology Laboratory, AvdaMestre José Veiga, 4715–330 Braga, Portugal, Department of Applied Physics, Technological Research Institute, Nanotechnology and Magnetism Lab—NANOMAG, University of Santiago de Compostela, 15782, Santiago de Compostela, Spain

  ⨯
• Rafael López-López,

  Affiliations Translational Medical Oncology, Health Research Institute of Santiago (IDIS); ComplexoHospitalarioUniversitario de Santiago de Compostela (SERGAS); Trav. Choupana s/n 15706, Santiago de Compostela, Spain, Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS); ComplexoHospitalarioUniversitario de Santiago de Compostela (SERGAS); Trav. Choupana s/n 15706, Santiago de Compostela, Spain

  ⨯
• Clotilde Costa

  * E-mail: ana.vila@inl.int (AV); clotilde.costa.nogueira@sergas.es (CC)

  Affiliation Translational Medical Oncology, Health Research Institute of Santiago (IDIS); ComplexoHospitalarioUniversitario de Santiago de Compostela (SERGAS); Trav. Choupana s/n 15706, Santiago de Compostela, Spain

  ⨯